Carl Rudolf Blankart

Biographic Data

ID9570484
NAMECarl Rudolf Blankart
GIVEN NAMESCarl Rudolf
FAMILY NAMEBlankart
SIGNATUREBLANKART C R
AFFILIATIONSUniversity of Bern
ORCID0000-0001-6719-0038
VERIFIEDYes
TOTAL WORKS11
TOTAL CITATIONS0
WORKS AS AUTHOR11
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2021
LATEST PUBLICATION YEAR2026
H-INDEX0

  • Implications of Primary Care Scenarios for the ‘Performance’ of Chronic Care Delivery in Switzerland

    Open AccessJohn Pastor Ansah, Lize Duminy et al.ARTICLESystems Research and Behavioral…2026

    Switzerland and most high‐income countries are confronted with a growing number of people with chronic conditions who must be treated by healthcare systems that are designed to provide acute care predominantly. A widely supported solution is strengthening the primary care sector to better meet these increasingly complex healthcare needs. We used system dynamics to develop a computer simulation model of the driving factors and their connections to…

  • The modernisation of newborn screening as a pan-European challenge – An international delphi study

    Open AccessSandra Gillner, Gulcin Gumus et al.ARTICLEHealth Policy2024

    Genomic sequencing holds transformative potential for newborn screening programmes. • International experts agree on the biggest barriers to fund genomic newborn screening. • Workforce education, counselling, and treatability are bottlenecks for genomic newborn screening. • Pan-European collaboration could help to overcome national bottlenecks of genomic newborn screening. Newborn screening is a public health measure to diagnose rare diseases at …

  • Identifying health inequities faced by older adults with rare diseases

    Open AccessJean Pierre Uwitonze, Lize Duminy et al.ARTICLEHealth Policy2024

  • Health literacy, governance and systems leadership contribute to the implementation of the One Health approach

    Open AccessCarl Rudolf Blankart, Saskia Maria De Gani et al.ARTICLEHealth Policy2024

    One Health is an important approach to addressing health threats and promoting health through interdisciplinary health, policy, legislation and leadership research to achieve better human and animal health and better outcomes for the planet. The Covid-19 pandemic has triggered an urgent awareness of the need to develop innovative integrative solutions to address root causes of such threats to health, which requires collaboration across discipline…

  • The challenges of regulatory pluralism

    Open AccessSandra Gillner, Katharina Blankart et al.ARTICLEHealth Policy2024

    Countries with small and/or less-resourced regulatory authorities that operate outside of a larger medical product regulatory system face a regulatory strategy dilemma. These countries may rely on foreign well-resourced regulators by recognising the regulatory decisions of large systems and following suit (regulatory reliance); alternatively, such countries may extend formal decision recognition to regulators in multiple other jurisdictions with …

  • Health Policy – the best evidence for better policies

    Open AccessWilm Quentin, Katharina Achstetter et al.ARTICLEHealth Policy2023

  • Why the US spends more treating high-need high-cost patients

    Open AccessLuca Lorenzoni, Alberto Marino et al.ARTICLEHealth Policy2023

    One of the most pressing challenges facing most health care systems is rising costs. As the population ages and the demand for health care services grows, there is a growing need to understand the drivers of these costs across systems. This paper attempts to address this gap by examining utilization and spending of the course of a year for two specific high-need high-cost patient types: a frail older person with a hip fracture and an older person…

  • How to pay primary care physicians for Sars-CoV-2 vaccinations

    Open AccessRicarda Milstein, Kosta Shatrov et al.ARTICLEHealth Policy2022

    Vaccinations are crucial to fighting SARS-CoV-2, and high coverage rates can in most countries probably only be achieved with the involvement of primary care physicians (PCPs). We aimed to explore how SARS-CoV-2 vaccination payment schemes in 43 countries differ with regard to the (i) type of payment scheme, (ii) amount paid, (iii) degree of bundling, and (iv) use of pay-for-performance elements. We collected information on payments and health sy…

  • After the four-year transition period

    Open AccessKosta Shatrov, Carl Rudolf BlankartARTICLEHealth Policy2022

  • Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges

    Open AccessRita Daubner-Bendes, Rita Daubner‐Bendes et al.ARTICLEFrontiers in Public Health2021

    Objectives: Methodological challenges in the evaluation of medical devices (MDs) may be different for early and late technology adopter countries, as well as the potential health technology assessment (HTA) solutions to tackle them. This study aims to provide guidance to Central and Eastern European (CEE) countries on how to address key challenges of HTA for MDs with special focus on the transferability of scientific evidence. Methods: As part of…

  • Regulatory and HTA early dialogues in medical devices

    Open AccessCarl Rudolf Blankart, Florian Dams et al.ARTICLEHealth Policy2021

    INTRODUCTION: Specific guidance and examples for health technology assessment (HTA) of medical devices are scarce in medical device development. A more intense dialogue of competent authorities, HTA agencies, and manufactures may improve evidence base on clinical and cost-effectiveness. Especially as the new Medical Device Regulation requires more clinical evidence. METHODS: We explore the perceptions of manufacturers, competent authorities, and …